GLPwatch

Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic.

BMB Rep · 2010

Last updated 2026-05-28

In a lab study, researchers combined a lizard-derived compound (exendin-4) with a human protein fragment to create a new compound called Ex-4/IgG-Fc. When tested in rat insulin cells, this compound increased the production of a protein (insulin receptor substrate-2) linked to better insulin function, suggesting it could act as a long-lasting GLP-1 drug.

AI summary of the abstract below.

JournalBMB Rep, 2010
Citations2
Relative citation ratio0.07
NIH percentile6
Molecules
Conditions studied Type 2 Diabetes

Abstract

Exendin-4 (Ex-4), a peptide secreted from the salivary glands of the Gila monster lizard, can increase pancreatic beta-cell growth and insulin secretion by activating glucagon-like peptide-1 receptor. In this study, we expressed a fusion protein consisting of exendin-4 and the human immunoglobulin heavy chain (Ex-4/IgG-Fc) in E. coli and explored its potential therapeutic use for the treatment of insulin-resistant type 2 diabetes. Here, we show that the Ex-4/IgG-Fc fusion protein induces expression of insulin receptor substrate-2 in rat insulinoma INS-1 cells. Our findings therefore suggest that Ex-4/IgG-Fc overexpressed in E. coli could be used as a potential, long-acting glucagon-like peptide-1 mimetic.

Verbatim abstract via PubMed 20193135 ↗